echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Oral FGFR inhibitors are eligible for FDA priority review for the treatment of bile tube cancer

    Oral FGFR inhibitors are eligible for FDA priority review for the treatment of bile tube cancer

    • Last Update: 2020-12-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    BridgeBio Pharma and its subsidiary QED Therapeutics announced that the FDA has accepted a new drug application (NDA) for the oral FGFR1-3 selective inhibitor infigratinib for the treatment of patients with cholangiocarcinoma.
    fda also granted this NDA priority review eligibility, while using the Real-Time Oncology Review (RTOR) pilot project for review.
    , BridgeBio will file regulatory applications in Australia and Canada under the Orbis project.
    is a cancer that occurs in the bile tubes of the liver and is a serious and often fatal disease that affects about 20,000 people in the United States and the European Union each year.
    about 15%-20% of patients carry the FGFR2 gene variant.
    currently, these patients have limited treatment options, with a five-year survival rate of only 9%.
    Infigratinib is an ATP competitive, FGFR1-3 oral tyrosine kinase inhibitor that is being developed to treat patients with FGFR-driven diseases, including bile tube cancer, urinary cort skin cancer, and cartilage dysplase development (a disease of bone growth in children).
    has teamed up with BridgeBio Pharma and QED Therapeutics to develop infigratinib in China and other Asian countries to treat cancers caused by mutations in the FGFR gene.
    In China, this innovative therapy was approved last week for clinical trials in patients with localized advanced or metastatic stomach cancer or gastroesophageal adenocarcinoma accompanied by other FGFR gene mutations.
    retrospective study published at this year's ANNUAL ASCO conference showed that infigratinib, a three-line or above monotherapy, had a median progression-free lifetime (PFS) of 6.8 months when treating patients with bile tube cancer that carried FGFR gene fusion.
    , the average PFS for patients with bile tube cancer who had historically underwent second-line chemotherapy was 4.6 months.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.